Aethlon Hemopurifier removes 99% of H5N1 in vitro; monitoring bird flu outbreak

AETHLON MEDICAL INC

In vitro study with scaled-down Hemopurifier showed 99% removal of H5N1 virus after 6 hours.
Device has not yet been used in human patients for H5N1; 38 patients treated for other enveloped viruses.
Hemopurifier holds FDA breakthrough device designation for life-threatening viruses with no effective treatment.
Company monitoring cases and engaging with hospitals, California, and FDA on potential use.
CDC recommends antivirals for H5N1; resistance observed in some hospitalized patients, suggesting need for novel therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.